A $65.9 million gain from a business sale largely drove Health Catalyst's $40.5 million profit.

Health Catalyst (HCAT) reported Q3 2026 revenue of $56.3M, down 26% YoY, but net income of $40.5M, driven by a $65.9M gain from a business sale. The company reaffirmed its full-year revenue guidance of $246M-$249M and Adjusted EBITDA of $18M-$18.5M. Management focuses on client retention and profitable revenue growth.

Original reporting
Published Nov 5, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HCAT
Neutral
high confidence
Mentioned
$HCAT
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$HCATNeutralHigh
01

Why it matters

The earnings release provides fresh profit numbers and guidance, offering traders a basis for short‑term positioning.

02

Market read

First‑report quarterly earnings with unexpected profit could move HCAT stock in after‑hours trading.

03

What to watch

Guidance reaffirmation and adjusted EBITDA guidance remain modest, indicating limited growth.

Relevance 7/10Novelty 8/10Timing: after-hours today

Background

Health Catalyst is a Nasdaq‑listed healthcare intelligence firm that provides data‑analytics platforms to health systems.

Company-level read

Ticker impact

$HCATNeutralHigh confidence
Context

Health Catalyst reported Q3 results with a $40.5M profit driven by a $65.9M gain from a business sale.

Expected impact

potential upside as market prices in better-than-expected profit

Evidence & confidence

First‑report earnings release with positive net income and guidance reaffirmation.

Market effects

May influence other healthcare‑technology stocks as earnings beat shows profitability path.

Limited to U.S. healthcare data‑analytics niche.

Low; primarily a company‑specific event.

Counterpoint

Profit driven by one-time sale may not be sustainable; revenue decline could pressure the stock.

Key entities

  • Simeon Kohl

    President and CEO of Health Catalyst, quoted in the release.

Related articles

$HCATMed

Health Catalyst Reports Third Quarter 2026 Results

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported finan

$HCATMedAI 8/10

Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.

$HCATHighAI 9/10

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.

$HCATMedAI 8/10

M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix

Health Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.